Complex | |
AACDB_ID: | 1194 |
PDBID: | 5B71 |
Chains: | DC_F |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.11 |
Reference: | 10.1038/s41598-017-01087-7 |
Antibody | |
Antibody: | SKY59 Fab |
Antibody mutation: | No |
INN (Clinical Trial): | Crovalimab(Approved) |
Antigen | |
Antigen: | Complement C5 beta chain |
Antigen mutation: | No |
Durg Target: | P01031 |
Antibody
Heavy Chain: D
Mutation: NULL
>5B71_D|Chain B, D|SKY59 Fab heavy chain|Homo sapiens (9606) QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP |
Light Chain: C
Mutation: NULL
>5B71_C|Chain A, C|SKY59 Fab light chain|Homo sapiens (9606) DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: F
Mutation: NULL
>5B71_F|Chain E, F|Complement C5 beta chain|Homo sapiens (9606) GSPEFEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYPDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPITYDNG |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
C: SER30 SER32 THR91 LYS92 VAL93 GLY94 SER95 TYR97 D: VAL29 HIS30 SER31 SER32 PHE53 GLY55 SER56 ALA58 TYR60 THR75 ASP100 GLY102 TYR103 TYR105 PRO106 THR107 HIS108 F: THR47 GLU48 ALA49 PHE50 ASP51 ALA52 THR53 SER55 SER65 SER68 HIS70 VAL71 HIS72 SER74 SER75 GLU76 VAL107 SER108 LYS109 HIS110 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)